Provided by: Chunghwa Chemical Synthesis & Biotech Co.,Ltd
SEQ_NO
1
Date of announcement
2022/08/01
Time of announcement
19:19:40
Subject
Announcement of the change of the general manager
Date of events
2022/08/01
To which item it meets
paragraph 6
Statement
1.Date of the board of directors resolution or date of occurrence of the
change:2022/08/01
2.Position (Please enter chairperson or president/general manager):
general manager
3.Name of the previous position holder:Jong-shinn Huang
4.Resume of the previous position holder:
General Manager, Chunghwa Chemical Synthesis & Biotech Co., Ltd.
5.Name of the new position holder:The new general manager will be
announced after the approval of the Board of Directors.
6.Resume of the new position holder:The new general manager will be
announced after the approval of the Board of Directors.
7.Circumstances of change (Please enter "resignation", "dismissal",
"term expired" , "job relocation", "severance", "retirement",
"death" or "new appointment"):resignation
8.Reason for the change:personal career planning
9.Effective date of the new appointment:will be announced after the
approval of the Board of Directors.
10.Any other matters that need to be specified:
(1)Effective date of resignation:2022/08/31
(2)The new general manager will be announced after the approval of
the Board of Directors.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Chunghwa Chemical Synthesis & Biotech Co. Ltd. published this content on 01 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 August 2022 11:24:04 UTC.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. 
